Ask AI

Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment

Gain a deeper understanding of the mechanisms of action and rationale for targeting TIGIT and TROP-2 in lung cancer based on recent clinical data and novel targeted therapies to increase clinical trial enrollment and enhance patient outcomes through a certified on-demand webcast, expert-authored ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

Events

  • Live Event Targeting TROP-2 and TIGIT
    Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

Targeting TROP2 and TIGIT in lung cancer
Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 28, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.